Variations in serum hemoglobin, albumin, and electrolytes in patients receiving intravenous immunoglobulin therapy: A real clinical threat?

American Journal of Clinical Dermatology

Volumn 8, Issue 5, 2007, Pages 291-299

  Mignogna, Michele D ^a,c   Fortuna, Giulio ^a   Ruoppo, Elvira ^a   Adamo, Daniela ^a   Leuci, Stefania ^a   Fedele, Stefano ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CALCIUM; CHLORIDE; CHLORPHENIRAMINE; CORTICOSTEROID; DEFLAZACORT; ELECTROLYTE; HEMOGLOBIN; HEPARIN CALCIUM; IG VENA N IV; IMMUNOGLOBULIN; MEPREDNISONE; PARACETAMOL; POTASSIUM; SERUM ALBUMIN; SODIUM; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOIMMUNE SKIN DISEASE; BIOCHEMISTRY; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; ELECTROLYTE BLOOD LEVEL; FEMALE; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HUMAN; LOW DRUG DOSE; MALE; MONITORING; MUCOUS MEMBRANE PEMPHIGOID; MULTIPLE CYCLE TREATMENT; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SUPPLEMENTATION;

EID: 35148835180     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200708050-00004     Document Type: Article

References (49)

1. Ballow M. Clinical and investigational considerations for the use of IGIV therapy. Am J Health Syst Pharm 2005; 62 (16 Suppl. 3): S12-8; quiz S19-21
2. Ahmed AR. Use of intravenous immunoglobulin therapy in autoimmune blistering diseases. Int Immunopharmacol 2006; 6: 557-78
3. Ahmed AR, Dahl MV, for the Consensus Development Group. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003; 139: 1051-9
4. Rutter A, Luger TA. Intravenous immunoglobulin: an emerging treatment for immune-mediated skin diseases. Curr Opin Investig Drugs 2002; 3: 713-9
5. Jolles S. A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders. Clin Exp Dermatol 2001; 26: 127-31
6. Harman KE, Black MM. High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases. Br J Dermatol 1999; 140: 865-74
7. Ahmed AR. Intravenous immunoglobulin therapy for patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001; 45: 679-90
8. Baum S, Scope A, Barzilai A, et al. The role of IVIg treatment in severe pemphigus vulgaris. J Eur Acad Dermatol Venereol 2006; 20: 548-52
9. Bystryn JC, Jiao D, Natow S. Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol 2002; 47: 358-63
10. Ahmed AR, Sami N. Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy. J Am Acad Dermatol 2002; 46: 42-9
11. Sami N, Bhol KC, Razzaque Ahmed A. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid. Clin Immunol 2002; 102: 59-67
12. Ahmed AR. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001; 45: 825-35
13. Gourgiotou K, Exadaktylou D, Aroni K, et al. Epidermolysis bullosa acquisita: treatment with intravenous immunoglobulins. J Eur Acad Dermatol Venereol 2002; 16: 77-80
14. Ahmed AR. Treatment of autoimmune mucocutaneous blistering diseases with intravenous immunoglobulin therapy. Expert Opin Investig Drugs 2004; 13: 1019-32
15. Weinberg MA, Insler MS, Campen RB. Mucocutaneous features of autoimmune blistering diseases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 84: 517-34
16. Hertl M, Eming R, Veldman C. T cell control in autoimmune bullous skin disorder. J Clin Invest 2006; 116: 1159-66
17. Yancey KB. The pathophysiology of autoimmune blistering diseases. J Clin Invest 2005; 115: 825-8
18. Sitaru C, Zillikens D. Mechanism of blister induction by autoantibodies. Exp Dermatol 2005; 14: 861-75
19. Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment and prognostic indicators. Arch Dermatol 2002; 138: 370-9
20. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340: 227-8
21. Jolles S, Sewell WAC, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 2005; 142: 1-11
22. Li N, Zhao M, Hilario-Vargas J, et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 2005; 115: 3440-50
23. Akilesh S, Petkova S, Sproule TJ, et al. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J Clin Invest 2004; 113: 1328-33
24. Mimouni D, Blank M, Ashkenazi L, et al. Protective effect of intravenous immu-noglobulin (IVIG) in an experimental model of pemphigus vulgaris. Clin Exp Immunol 2005; 142: 426-32
25. Arredondo J, Chernyavsky AI, Karaouni A, et al. Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in pemphigus. Am J Pathol 2005; 167: 1531-44
26. Bystryn JC, Jiao D. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris. Autoimmunity 2006; 39: 601-7
27. Bystryn JC, Rudolph JL. IVIg treatment of pemphigus: how it works and how to use it. J Clin Invest 2005; 125: 1093-6
28. Boros P, Gondolesi G, Bromberg JS. High dose intravenous immunoglobulin treatment: mechanisms of action. Liver Transpl 2005; 11: 1469-80
29. Berlana D, Vidaller A, Jodar R, et al. Changes in biochemical, hematological and immunological profiles after low-dose intravenous immunoglobulin administration in patients with hypogammaglobulinemia. Trans Clin Biol 2005; 12: 433-40
30. Knezevic-Maramica I, Kruskall MS. Intravenous immune globulins: an update for clinicians. Transfusion 2003; 43: 1460-80
31. Orbach H, Katz U, Sherer Y, et al. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005; 29: 173-84
32. Lee KY, Han JW, Lee JS, et al. Alteration of biochemical profiles after high-dose intravenous immunoglobulin administration in Kawasaki disease. Acta Paediatr 2002; 91: 164-7
33. Ng SK. Intravenous immunoglobulin infusion causing pseudohyponatremia. Lupus 1999; 8: 488-90
34. Nguyen MK, Rastogi A, Kurtz I. True hyponatremia secondary to intravenous immunoglobulin. Clin Exp Nephrol 2006; 10: 124-6
35. Steinberger BA, Ford SM, Coleman TA. Intravenous immunoglobulin therapy results in post-infusional hyperproteinemia, increased serum viscosity, and immupseudohyponatremia. Am J Hematol 2003; 73: 97-100
36. Kessary-Shoham H, Levy Y, Shoenfeld Y, et al. In vivo administration of intrave-nous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration. J Autoimm 1999; 13: 129-35
37. Shoham-Kessary H, Naot Y, Gershon H. Immune complex-like moieties in immunoglobulin for intravenous use (IVIg) bind complement and enhance phagocytosis of human erythrocytes. Clin Exp Immunol 1998; 113: 77-84
38. Katz U, Shoenfeld Y. Review: intravenous immunoglobulin therapy and thromboembolic complications. Lupus 2005; 14: 802-8
39. Paran D, Herishanu Y, Elkayam O, et al. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis 2005; 16: 313-8
40. Gelfand EW. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol 2006; 6: 592-9
41. Mckay LI, Cidlowsky JA. Corticosteroids. In: Holland JF, Frei E III, editors. Cancer medicine. 5th ed. London: BC Decker, 2000: 730-43
42. Gaffney K, Scott DG. Azathioprine and cyclophosphamide in the treatment of rheumatoid arthritis. Br J Rheumatol 1998; 37: 824-36
43. Oren RM. Hyponatremia in congestive heart failure. Am J Cardiol 2005; 95 Suppl.: 2-7B
44. Anderson CL, Chaudhury C, Kim J, et al. Perspective: FcRn transports albumin. Relevance to immunology and medicine. Trends Immunol 2006; 27: 343-8
45. Chaudhury C, Mehnaz S, Robinson JM, et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med 2003; 197: 315-22
46. Israel EJ, Wilsker DF, Hayes KC, et al. Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn. Immunology 1996; 89: 573-8
47. Katz U, Achiron A, Sherer Y, et al. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007; 6: 257-9
48. Mahieu AC, Sisti AM, Joekes S, et al. Pharmacovigilance study of a regional intravenous immunoglobulin (II): evaluation and comparison of an improved pharmaceutical form. Allergol Immunopathol (Madr) 2006; 34: 242-7
49. Katz U, Kishner I, Magalashvili D, et al. Long term safety of IVIg therapy in multiple sclerosis: 10 years experience. Autoimmunity 2006; 39: 513-7